Im, Young-Hyuck http://orcid.org/0000-0001-6459-8118
Karabulut, Bulent
Lee, Keun Seok
Park, Byeong-Woo
Adhav, Aditya
Cinkir, Havva Yesil
Abdel-Razeq, Hikmat
Chang, Yuan-Ching
Aksoy, Sercan
Im, Seock-Ah
Jeong, Joon
Chae, Yeesoo
Bowles, James
Slimane, Khemaies
Xue, Hongling
Kim, Sung-Bae
Funding for this research was provided by:
Novartis Pharma AG, Basel, Switzerland
Article History
Received: 28 December 2020
Accepted: 3 March 2021
First Online: 16 March 2021
Compliance with ethical standards
:
: SA has received personal fees from Roche, Merck, Eli Lilly, Abdi Ibrahim AS, BMS, Novartis, Pfizer, Mustafa Nevzat İlaç Sanayii. SBK has received grant from Novartis, Sanofi-Aventis, Kyowa-Kirin Inc, Dongkook Pharm Co, others from Novartis, Personal fees from Astra-Zeneca, Eli Lilly, Enzychem, Dae Hwa Pharmaceutical Co Ltd, ISU Abix, and Daiichi-Sankyo. KSL has received personal fees from Roche, Novartis, Lilly and nonfinancial support from Dong-A Pharm. SAI has received grant from AstraZeneca, Roche, Pfizer, personal fees from Novartis, and others from Amgen, Eisai, Hanmi, and Novartis. JB, KS, and HX are Novartis employees. FR owns Novartis stocks. All other authors declare no conflict of interest.
: Ethics approval was obtained at each participating center for the collection of the data described in this report.
: Informed consent was obtained from each participant for inclusion in this research.